Abbott LaboratoriesvsZevra Therapeutics

ABT and ZVRA stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.41

Value $181B

+0.51%
ABT's page

ZVRA

Zevra Therapeutics, Inc.

$8.87

Value $521M

-2.21%
ZVRA's page

Abbott Laboratories (ABT) has a market value of $181B and Zevra Therapeutics (ZVRA) $521M. Over the last year, with dividends, ABT moved -15.2% and ZVRA -8.4%. The P/E is 38.6 for ABT and 6.8 for ZVRA. Dividend yield: ABT 2.41%, ZVRA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$181B

    ZVRA$521M

    ABT is 348 times ZVRA

  • Revenue, 12 months

    ABT$48.2B

    ZVRA$148M

    ABT is 326 times ZVRA

  • Net income, 12 months

    ABT$4.7B

    ZVRA$78M

    ABT is 60 times ZVRA

  • Operating margin

    ABT13.8%

    ZVRA60.8%

    47.0 points apart

  • ROIC

    ABT6.3%

    ZVRA36.3%

    30.0 points apart

  • P/E

    ABT38.6

    ZVRA6.8

    ABT is 5.7 times ZVRA

  • Dividend yield

    ABT2.4%

    ZVRA0.0%

    2.4 points apart

  • 5-year return

    ABT-9.1%

    ZVRA+5.6%

    14.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-9.1%

ZVRA+5.6%

5010015020222023202420252026
Returns by period
PeriodABTWith dividendsZVRAWith dividends
1 year since November 19, 2025-15.2%Price -17.2%-8.4%Price -8.4%
3 years since November 20, 2023+9.9%+3.2% a yearPrice +3.2%+98.0%+25.6% a yearPrice +98.0%
5 years since November 19, 2021-9.1%-1.9% a yearPrice -17.7%+5.6%+1.1% a yearPrice +5.6%
10 years since November 21, 2016+216.8%+12.2% a yearPrice +162.6%-86.5%-18.1% a yearPrice -86.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesZVRAZevra Therapeutics

Valuation

ABTZVRA
Valuation
Price$104.41$8.87
Market value$181B$521M
Enterprise value (EV)$208B$325M
P/E38.66.8
P/E, 5-year median33.7–
P/B3.62.2
EV/EBIT31.33.6
Free cash flow yield3.7%7.4%

Results and growth

ABTZVRA
Results and growth
Revenue, 12 months$48.2B$148M
Net income, 12 months$4.7B$78M
Free cash flow, 12 months$6.8B$38M
Earnings per share, 12 months$2.69$1.19
Revenue growth, year on year5.7%350.9%
Revenue growth a year, past+5.1%over 5 years+51.6%over 5 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTZVRA
Margins and returns on capital
Gross margin56.9%95.4%
Operating margin13.8%60.8%
Net margin9.8%52.8%
ROIC6.3%36.3%
ROE9.1%41.1%

Balance sheet

ABTZVRA
Balance sheet
Cash$4.3B$196M
Total debt$31.2B$1.2M
Net debt / EBITDA3.3-2.1
Interest cover6.7×24.6×

Dividends and buybacks

ABTZVRA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or ZVRA

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Zevra Therapeutics?

By market value, Abbott Laboratories ($181B) is about 348.4 times Zevra Therapeutics ($521M), at today's prices.

How did ABT and ZVRA stock do over the last 10 years?

Since November 21, 2016, ABT's price moved +162.6% and ZVRA's -86.5%. With dividends: ABT +216.8% (+12.2% a year), ZVRA -86.5% (-18.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or ZVRA?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Zevra Therapeutics. Over the last twelve months they paid $2.52 and – per share.

What is the P/E of ABT and ZVRA?

At today's price, the P/E is 38.6 for ABT and 6.8 for ZVRA. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Abbott Laboratories or Zevra Therapeutics?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 52.8% for Zevra Therapeutics, and the operating margin 13.8% and 60.8%. Revenue was $48.2B and $148M.

Which is the better investment, Abbott Laboratories or Zevra Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.